An independent peptide reference — no sellers, every claim sourced

Carnosine

Also known as Beta-alanyl-L-histidine, L-carnosine, Ignotine

Endogenous dipeptide used topically against glycation and taken orally, where serum carnosinase destroys most of it.

early-clinical Skin & cosmetic cosmetic ingredient

At a glance

Category
Skin & cosmetic
Status
cosmetic ingredient
Route
topical in creams and serums; also taken orally as a supplement
Half-life
In human plasma, only minutes after oral dosing, because serum carnosinase hydrolyses it almost immediately 14; the carnosinase-resistant analogue balenine has a plasma half-life roughly thirty times longer, which is the comparison that makes the point 4. Not applicable to topical use, where systemic absorption is negligible — carnosine has been shown not to penetrate beyond the stratum corneum 5
Onset
Topical studies and product trials assessed change over 4 to 14 weeks; for oral use there is no established onset because there is no established systemic effect
Molecular weight
226.2 g/mol (C9H14N4O3)
Sequence
Beta-Ala-His (beta-alanyl-L-histidine)

Carnosine occupies three categories at once and it is worth being precise about which is which. It is an endogenous dipeptide, present in human skeletal muscle at millimolar concentrations and also in brain and heart tissue 1. It is registered as a cosmetic ingredient under the INCI name carnosine and used topically in anti-ageing formulations. And it is sold as an oral food supplement. It is not a medicine in any of these roles: no medicines authority has approved it for any indication, and the cosmetic and supplement claims made for it have not been assessed by one.

Doping status: Not listed by WADA

Checked against the WADA 2026 Prohibited List. For a specific product and country, Global DRO is the lookup athletes are expected to use — the List names substances, not brand names.

Mechanism of action

Carnosine is a dipeptide of beta-alanine and L-histidine. Its chemistry is well characterised and genuinely interesting: the imidazole ring of the histidine residue gives it a pKa close to physiological pH, making it an effective intracellular proton buffer, and it chelates transition metals such as copper and zinc, which suppresses metal-catalysed oxidative reactions.

The property behind the cosmetic use is carbonyl scavenging. Carnosine reacts with reactive carbonyl species such as methylglyoxal and acrolein, which are the intermediates that cross-link proteins into advanced glycation end-products. In skin, AGE accumulation on long-lived dermal collagen is one of the better-supported mechanisms of intrinsic ageing, because cross-linked collagen is stiffer and less able to be remodelled. Carnosine is therefore positioned as an anti-glycation agent rather than as a signalling peptide: it is meant to intercept the damaging chemistry, not to instruct fibroblasts to do anything. This distinguishes it clearly from matrikine peptides such as palmitoyl tripeptide-1 and from the SNARE-targeting peptides such as argireline.

Orally, the story is dominated by one enzyme. Human plasma contains serum carnosinase 1 (CN1, gene CNDP1), a highly active dipeptidase that hydrolyses circulating carnosine into beta-alanine and histidine within minutes 1. Humans are unusual in this: most other mammals have far lower serum carnosinase activity, which is why animal data on oral carnosine translate poorly 1. The practical consequence is that swallowing carnosine mostly delivers its two constituent amino acids to the tissues rather than the intact dipeptide, and the rate-limiting step for muscle carnosine synthesis is beta-alanine availability 16. That is why sports-science practice uses beta-alanine, not carnosine, to raise muscle carnosine content 6.

Some carnosine does survive long enough to react. Intervention work has detected carnosine-acrolein adducts in urine after oral dosing, showing that at least a fraction scavenges carbonyls before being hydrolysed 2. Whether that fraction is large enough to matter clinically is an open question. Related compounds that resist carnosinase — anserine, and particularly balenine, whose plasma half-life is roughly thirty times longer 4 — are being investigated precisely because of this limitation.

What the research shows

The chemistry is solid and independently established. The topical anti-glycation effect has been shown in human skin explants in a peer-reviewed study, but that was ex vivo and industry-affiliated, and clinical wrinkle data come only from multi-ingredient products. For oral use, the pharmacokinetics are well documented and unfavourable: most of an oral dose is destroyed by serum carnosinase within minutes, and claims of systemic anti-ageing benefit are not supported by adequate trials.

Research in humans

Topical: a 2018 study in Skin Pharmacology and Physiology applied a carnosine-containing facial cream to human skin explants in which glycation had been induced with methylglyoxal, and reported substantial reductions in the AGE markers carboxymethyl-lysine and pentosidine in both epidermis and reticular dermis, with the cream formulation outperforming carnosine in plain aqueous solution 3. That is an ex-vivo explant model, not a clinical trial, and the authors were affiliated with the manufacturer 3. Clinical data on wrinkles come from multi-ingredient serums combining carnosine with retinol and other actives, from which carnosine's own contribution cannot be extracted. Oral: a 2016 intervention study in Scientific Reports gave overweight volunteers 2 g per day for twelve weeks and found carnosine-acrolein adducts in the urine of all subjects, confirming that some carbonyl scavenging occurs, while also confirming that intact plasma carnosine is essentially undetectable 2. Trials of oral carnosine in glucose control, cognition and other endpoints exist but are small, heterogeneous and not consistently replicated.

Animal and lab research

Extensive, and largely unusable for extrapolation. Rodents and most other mammals have much lower serum carnosinase activity than humans, so animal studies showing systemic effects of oral carnosine describe a pharmacokinetic situation that does not exist in people. This is one of the clearer cases in the supplement literature where positive animal data should not be read across.

Caveats. For topical use: an explant model is not skin on a living face, the study was industry-affiliated, and no independent randomised controlled trial of carnosine alone on human facial skin has been published. Penetration of a small, charged, hydrophilic dipeptide through the stratum corneum is not favourable on physicochemical grounds, and the cream formulation outperforming the aqueous solution in the explant study is consistent with formulation mattering a great deal. For oral use: the serum carnosinase problem is not a minor caveat but the central fact, and carnosinase activity varies substantially between individuals, meaning results are unlikely to be uniform. Much of the enthusiasm for oral carnosine rests on in-vitro chemistry and animal work rather than on human outcome data.

What it is used for

  • Topical anti-ageing formulations, positioned against glycation-related loss of skin elasticity rather than against expression lines
  • Frequently combined with retinol, niacinamide or antioxidants in finished products
  • Oral supplement, taken in the hope of systemic anti-glycation, antioxidant or cognitive effects — a use undermined by rapid hydrolysis by serum carnosinase 12
  • Beta-alanine is used instead of carnosine when the goal is specifically to raise muscle carnosine content, because beta-alanine availability is the rate-limiting step 16
  • N-acetylcarnosine eye drops are a separate product with a separate and weak evidence base, and should not be assumed to work because carnosine chemistry is sound

Dosing

Dose
Topical: typically 0.5 to 2 percent carnosine in the finished formulation. Oral: supplement products commonly provide 500 mg to 2 g per day; the published intervention study used 2 g per day
Frequency
Topical once to twice daily; oral usually in one or two divided doses
Route
topical for the cosmetic use; oral for the supplement use. It is not an injectable peptide
Duration
Topical studies and product trials ran 4 to 14 weeks. The oral bioavailability study ran twelve weeks
  • This is emphatically not an injectable. Injecting a cosmetic peptide solution has never been studied in humans, and cosmetic trade solutions are not sterile and not pyrogen-free.
  • Topical use levels come from supplier formulation guidance and from the concentrations used in explant work 3, not from clinical dose-finding.
  • Oral doses come from supplement convention and from a small number of research protocols — the published bioavailability study used 2 g per day for twelve weeks 2 — not from a validated clinical dosing schedule. Higher oral doses do not overcome serum carnosinase in most people; the enzyme is fast and abundant 1.
  • If the goal is muscle carnosine, beta-alanine is the intervention with actual supporting evidence — not oral carnosine. The International Society of Sports Nutrition position stand puts the effective dose at 4 to 6 g daily for at least 2 to 4 weeks 6. Beta-alanine causes transient paraesthesia, which the same document says can be minimised by splitting the dose into portions of about 1.6 g or by using a sustained-release form 6.
  • Dietary intake matters more than it does for most peptides: red meat and fish contain carnosine and related dipeptides in meaningful amounts, and vegetarians have lower muscle carnosine.

These figures describe what the literature and published protocols report. They are not advice and not a dosing instruction.

Reconstitution

Vial sizes
Sold as a bulk crystalline powder for formulators and as capsules or tablets for oral use; not supplied in vials for reconstitution
Solvent
water or the aqueous phase of an emulsion; not bacteriostatic water for injection — this ingredient is not reconstituted for injection
Storage
Store the powder dry, cool and dark. Carnosine is reasonably stable as a dry solid but an aqueous solution requires a preservative system in any finished product.

Worked example

For a finished cream, carnosine powder is dissolved in the water phase at roughly 0.5 to 1 percent of total weight before emulsification or added to the cooled aqueous phase, after which the pH is set to approximately 5 to 6.

Freely water-soluble, which makes it easy to formulate but does not favour skin penetration; the explant study found the cream base markedly outperformed a plain aqueous solution, so the vehicle is not a detail. Avoid strongly alkaline phases and prolonged heating.

Safety

Side effects

  • Topical: generally well tolerated; mild redness or tingling at the application site. Cosmetic peptides as a class perform well in standard skin and eye irritation testing 5
  • Contact allergy is rare — peptides are typically not electrophilic and so lack the reactivity that drives delayed-type hypersensitivity 5 — and reactions are more often to preservatives, fragrance or other actives in the same product
  • Oral: usually well tolerated at supplement doses; occasional gastrointestinal upset has been reported. Beta-alanine, the amino acid an oral carnosine dose largely becomes, is described as safe in healthy populations at recommended doses 6
  • Oral doses effectively deliver beta-alanine and histidine after hydrolysis 1; at high doses this can produce the paraesthesia (tingling of the face, scalp and hands) characteristic of beta-alanine — the only adverse effect the ISSN position stand reports for it 6 — though less readily than beta-alanine itself
  • Long-term systematic safety data for daily oral use over years are limited

Do not use if

  • Known hypersensitivity to the ingredient or to the formulation
  • Topical: damaged, inflamed or freshly treated skin, for example after a peel or laser treatment; do not apply to mucous membranes or in the eyes
  • Injecting this ingredient has never been studied in humans, and cosmetic trade solutions are not sterile or pyrogen-free — a real infection and pyrogen risk, not a theoretical one
  • Histidinaemia and other disorders of histidine metabolism: oral carnosine is a histidine source and has not been studied in these conditions
  • Pregnancy and breastfeeding: no specific research for either the topical or the oral use, although systemic exposure from topical use is negligible — carnosine has been shown not to penetrate beyond the stratum corneum 5
  • People taking medication for blood glucose control should be aware that small trials have reported effects on glycaemic measures with oral carnosine; this has not been characterised well enough to be relied on in either direction

Interactions

With topical use no systemic drug interactions are expected, because a topically applied cosmetic peptide is not expected to reach the systemic circulation at all, and carnosine specifically has been shown not to penetrate beyond the stratum corneum 5. With oral use, the main pharmacological interaction is with the body's own serum carnosinase rather than with any drug 1: co-ingestion of anserine or other carnosinase substrates competes for the enzyme and raises plasma carnosine somewhat 4, which is a research strategy rather than a supplement recommendation. Small trials have reported changes in glycaemic parameters with oral carnosine, so caution is reasonable alongside glucose-lowering medication. No systematic drug interaction studies exist.

Sources